GTBP GT Biopharma Inc

GT Biopharma, Inc. engages in the development and commercialization of novel immuno-oncology products. Its products include OXS-1550, OXS-1615, OXS-3550, OXS-3550, PainBrake, GTP-004, and GTP-011. The company was founded in 1965 and is headquartered in Beverly Hills, CA.

$1.43  +0.09 (6.72%)
As of 12/07/2022 16:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/31/1969
Outstanding shares:  32,557,720
Average volume:  50,002
Market cap:   $43,627,345
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BMBZM12
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy